Awareness Raising

Iron deficiency with or without anaemia in IBD

P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey

Iron deficiency (ID) and iron deficiency anaemia (IDA) are conditions frequently observed in patients with inflammatory bowel disease (IBD) and require appropriate treatment. This study investigated patient and physician perspectives on the management of these conditions.

Read time: 1 min

Patient Safety: Biologics and Biosimilars

Since about 2015 the issue on biologics and biosimilars has received a lot of attention from the medical, regulatory and patient community. Licensing rights of biological medicines used in the treatment not only of IBD but also other autoimmune modulated diseases are coming to an end and biosimilars medicines are being developed to compete with original biological treatment options. In various countries in the EU and elsewhere biosimilars have already entered the market.  

Read time: 4 mins

Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease

P328 Patient and physician perspectives on managing iron deficiency with or without anaemia in inflammatory bowel disease: findings from a European online survey 

January, 2017

Iron deficiency (ID) and iron deficiency anaemia (IDA) are conditions frequently observed in patients with inflammatory bowel disease (IBD) and require appropriate treatment. This study investigated patient and physician perspectives on the management of these conditions.

Read time: 1 min

Patient Perspectives on Biosimilars

Patient Perspectives on Biosimilars: A Survey by the European Federation of Crohn's and Ulcerative Colitis

July, 2016

The aim of this survey was to find out the patients' perspectives concerning biosimilars. An online survey consisting of 14 questions was made available between November 2014 and October 2015. Only respondents who had heard of biosimilars were asked to respond the final twelve questions.

Read study

Read time: 1 min

IBD and health-related quality of life — Discovering the true impact

IBD and health-related quality of life — Discovering the true impact 

October, 2014

Although inflammatory bowel diseases (IBD) significantly impact the patient's quality of life, no European-level data exists on patients’ perspectives. The primary objective of this survey was to obtain an international perspective of the impact of IBD on patients’ lives. Secondary objectives included obtaining a better understanding of the quality of care, access to care, and differences between countries, age groups, and sub-groups of IBD. 

Read time: 1 min

Discover the true effect of anaemia in IBD

As many of us unfortunately know, fatigue is said to be one of the ‘big three’ symptoms of IBD (pain, fatigue, and urgently needing the toilet).

As several important articles note that anaemia may be especially significant in people with IBD, EFCCA, supported by Vifor Pharmaceuticals and A+A Research, carried out a survey to understand:

  • The effects of anaemia in IBD from the patient’s perspective

  • The effect of fatigue on a variety of activities in daily life

  • How healthcare professionals approach and communicate anaemia in IBD

Read time: 3 mins